Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention

Jin Hee Choi, Kook Jin Chun*, Soon Myung Jung, Soo Yong Lee, Min Ku Chon, Sang Hyun Lee, Ki Won Hwang, Jeong Su Kim, Yong-Hyun Park and June Hong Kim

Abstract

Background: Compared to simple percutaneous coronary intervention (PCI), complex PCI is associated with higher bleeding and thrombotic risk. No previous study has evaluated the use of protamine after PCI with contemporary technologies. This study aimed to evaluate the safety and efficacy of manual compression with and without protamine after transfemoral complex PCI.

Methods: We retrospectively analyzed 160 patients (protamine group, n = 92; non-protamine group, n = 68) who underwent complex PCI via the femoral artery. The primary outcome was a composite of in-hospital death, myocardial infarction, stent thrombosis, stroke/systemic embolism, bleeding requiring blood transfusion, and vascular access complications.

Results: The primary outcome was significantly lower in the protamine group than in the non-protamine group (4.3% vs. 17.6%; p = 0.006). This was driven mainly by the lower incidences of hematoma in the protamine group (3.3% vs. 13.2%, p = 0.020). Furthermore, the protamine group had a significantly shorter hospital stay than the non-protamine group (4.8 ± 3.7 days vs. 8.4 ± 8.3 days, p = 0.001). While > 90% of the patients had acute coronary syndrome, there were no incidences of myocardial infarction or stent thrombosis in either group.

Conclusions: Among patients who underwent complex PCI via transfemoral access, immediate protamine administration was associated with a significantly lower rate of vascular access complications, especially hematoma, and shorter hospital stay than no protamine administration.

Keywords: Anticoagulant, Bleeding, Percutaneous coronary intervention, Protamine

Background

Complex percutaneous coronary intervention (PCI) is likely to increase the risk of bleeding complications due to the use of larger French sheath systems via a transfemoral approach, dual access, and a large volume of heparin [1, 2]. Therefore, complete hemostasis after femoral sheath removal is the most crucial factor. Although vascular closure devices can be used to achieve early hemostasis and ambulation compared to manual compression, these devices still have rare but serious complications, including groin infection, distal ischemia, and localized thrombosis [3]. Furthermore, the calcified or small size of the femoral artery has some limitations in using the vascular closure devices, which eventually require manual compression in challenging cases [4]. Patients with successful complex PCI remain at increased risk of bleeding and stent thrombosis due to incomplete stent
expansion, bifurcation stenting, and use of multiple long stents. Several studies have shown that immediate anticoagulant reversal with protamine and sheath removal is a safe alternative to standard manual compression after PCI [5–7]. As complex PCI itself has a higher thrombotic risk than simple PCI, the use of protamine is expected to increase the risk of stent thrombosis. To our knowledge, no previous study has evaluated the immediate use of protamine after complex PCI using contemporary technologies. Therefore, we evaluated the safety and efficacy of transfemoral PCI in patients with complex coronary lesions using manual compression with or without protamine.

Methods
From January 2015 to December 2019, 3976 consecutive patients (7007 lesions) underwent PCI at the Pusan National University Yangsan Hospital. The inclusion criteria were (1) femoral artery puncture requiring a >7-Fr guiding system; (2) complex PCI, which was defined as a procedure with at least one of the following angiographic characteristics: unprotected left main disease, ≥3 lesions treated, lesion length ≥60 mm, bifurcation treated with two-stent technique, or chronic total occlusion (CTO) lesions as the target lesion; and (3) manual compression, which was not suitable for arterial closure devices such as Perclose Proglide (Abbott Vascular Devices, Redwood City, CA, USA) and Angio-Seal (Terumo Medical Corporation, Somerset, NJ, USA) because of access site locations, dense calcifications, and small size of the femoral artery. The exclusion criteria were as follows: (1) use of oral anticoagulants, (2) presence of an intracoronary thrombus, and (3) hemodynamic instability. In this study, only the first PCI was considered for analysis for patients who underwent multiple PCI. A total of 160 patients who met the inclusion and exclusion criteria were retrospectively analyzed. The study population was divided into patients who received protamine (protamine group) and those who did not receive protamine (non-protamine group). This study was approved by the Pusan National University Yangsan Hospital Institutional Review Board (IRB No. 05-2020-105), and the requirement for written informed consent was waived because of the retrospective study design.

The baseline clinical and procedural data were retrospectively collected. The primary outcome was a composite of in-hospital death, myocardial infarction (MI), stent thrombosis, stroke/systemic embolism (SSE), bleeding requiring blood transfusion, and vascular access complications. Vascular access complications were defined as the presence of a major groin hematoma (>5 cm in diameter), pseudoaneurysm, arteriovenous fistula, or surgical repair. Protamine-related adverse effects included hypotension, bradycardia, anaphylactic reactions, and pulmonary hypertension.

Before the procedure, all patients received dual antiplatelet therapy (DAPT), including clopidogrel (loading dose, 600 mg; maintenance dose, 75 mg once daily), ticagrelor (loading dose 180 mg, maintenance dose 75 mg twice daily), or prasugrel (loading dose 60 mg, maintenance dose 10 mg once daily) with acetylsalicylic acid (loading dose 300 mg, maintenance dose 100 mg daily). PCI was performed using standard techniques. Unfractionated heparin was administered as an initial bolus of 70–100 U/kg, and additional boluses were administered during the procedure to achieve an activated clotting time (ACT) of 250–300 s. The choice of stent type and device was left to the discretion of the interventional cardiologist. Intravascular ultrasound (IVUS)-guided PCI was performed in all patients. A successful angiographic procedure was defined as residual stenosis <30%, TIMI grade 3 distal flow, and absence of significant dissection. At the end of PCI, the ACT was checked. The use of protamine was maintained at the physician's discretion. If ACT was <200 s, no protamine was administered. If ACT was ≥200 s, 25–50 mg of protamine (diluted in 100 mL of 0.9% normal saline) was administered intravenously for 10 min. The protamine injection rate was maintained at ≤10 mg/min to avoid hypotension and pulmonary edema [8, 9]. In the protamine group, the sheath was removed immediately after protamine administration. In the non-protamine group, the sheath was generally removed 2–3 h after PCI. Hemostasis was achieved using manual compression or mechanical compression devices, such as a C-shaped clamp. After compression, all patients were instructed to take absolute bed rest for 4–5 h, with a sandbag placed on the puncture site.

Statistical analysis
All continuous variables are expressed as the mean ± standard deviation. Normally and non-normally distributed continuous variables were compared using the Student's t-test and Mann–Whitney U test, respectively. Categorical variables were expressed as absolute numbers (frequency) and percentages and compared using Pearson's chi-square test or Fisher's exact test. Independent predictors of the primary outcome were identified by first including the parameters in a univariate regression analysis and subsequently entering the significant predictors in a stepwise multivariate logistic regression model. Statistical significance was defined as a two-tailed p value of ≤0.05. Statistical analyses were performed using SPSS version 18.0 for Windows (IBM Corp., Armonk, NY, USA).
Results
A total of 160 patients were enrolled and divided into the protamine group (n = 92) and the non-protamine group (n = 68). The baseline patient characteristics are shown in Table 1. The demographic and clinical characteristics were balanced between the two groups. The mean age was 68.6 ± 10.4 years and 67.5% of patients were male. Notably, more than 90% of the patients in both groups had acute coronary syndrome (ACS) (91.3% in the protamine group and 95.6% in the non-protamine group).

The angiographic and procedural characteristics of the two groups are shown in Table 2. The non-protamine group had more unprotected left main disease cases than the protamine group (29.4% vs. 17.4%, p = 0.072). There were significantly more cases of CTO as a target lesion treated in the protamine group than in the non-protamine group (62.0% vs. 30.9%, p < 0.001). All patients underwent IVUS-guided PCI using second-generation drug-eluting stents (DES).

The primary outcome was significantly lower in the protamine group than in the non-protamine group (4.3% vs. 17.6%, p = 0.006) (Table 3, Fig. 1). The significantly lower rates in the protamine group were driven mainly by lower rates of hematoma in the protamine group than in the control group (3.3% vs. 13.2%, p = 0.020). No stent thrombosis or MI was observed in either group. There were no adverse reactions related to protamine, such as hypotension, bradycardia, anaphylactic reaction, bronchospasm, and pulmonary hypertension. In addition, the protamine group had a significantly shorter length of in-hospital stay than the non-protamine group (4.8 ± 3.7 vs. 8.4 ± 8.3 days, p = 0.001).

Univariate and multivariate analyses revealed that only the administration of protamine (odds ratio, 0.138; 95% confidence interval: 0.036–0.526; p = 0.004) was independently associated with the primary endpoint (Fig. 2).

Discussion
The main findings of our study, with a total of 160 patients undergoing transfemoral PCI for complex lesions, are as follows: (1) immediate administration of protamine resulted in significantly lower rates of the composite of in-hospital death, MI, stent thrombosis, stroke/systemic embolism, bleeding requiring blood transfusion, and vascular access complications; (2) use of protamine after PCI was safe with lower rates of

Table 1 Baseline demographic and clinical characteristics of patients in the protamine and non-protamine groups

|                                | All (n = 160) | Protamine group (n = 92) | Non-protamine group (n = 68) | p value |
|--------------------------------|--------------|-------------------------|-----------------------------|---------|
| Age, years                     | 68.6 ± 10.4  | 68.1 ± 10.9             | 69.2 ± 9.7                  | 0.518   |
| Male sex                       | 108 (67.5)   | 61 (66.3)               | 47 (69.1)                   | 0.707   |
| Body mass index, kg/m²         | 24.2 ± 3.4   | 24.4 ± 3.2              | 23.9 ± 3.5                  | 0.329   |
| Smoking                        | 43 (26.9)    | 27 (29.3)               | 16 (23.5)                   | 0.412   |
| Cardiac or coexisting conditions |              |                         |                             |         |
| Hypertension                   | 103 (64.4)   | 57 (62.0)               | 46 (67.6)                   | 0.457   |
| Diabetes mellitus              | 76 (47.5)    | 38 (41.3)               | 38 (55.9)                   | 0.068   |
| Chronic kidney disease         | 31 (19.4)    | 15 (16.3)               | 16 (23.5)                   | 0.253   |
| Previous myocardial infarction | 18 (11.3)    | 12 (13.0)               | 6 (8.8)                     | 0.404   |
| Previous PCI                   | 32 (20.0)    | 20 (21.7)               | 12 (17.6)                   | 0.522   |
| Previous CABG                  | 7 (4.4)      | 5 (5.4)                 | 2 (2.9)                     | 0.700   |
| Dyslipidemia                   | 79 (49.4)    | 44 (47.8)               | 35 (51.5)                   | 0.649   |
| Hemoglobin, g/dL               | 12.1 ± 2.4   | 12.0 ± 2.5              | 12.1 ± 2.2                  | 0.783   |
| Platelet, x 10³ cells/mL       | 219.1 ± 64.8 | 219.9 ± 61.3            | 218.0 ± 69.7                | 0.855   |
| Left ventricular ejection fr. %| 54.3 ± 12.5  | 54.6 ± 12.4             | 53.9 ± 12.7                 | 0.721   |
| Clinical presentation          |              |                         |                             |         |
| Stable CAD                     | 11 (6.9)     | 8 (8.7)                 | 3 (4.4)                     | 0.357   |
| ACS*                           | 149 (93.1)   | 84 (91.3)               | 65 (95.6)                   |         |
| Dual antiplatelet therapy      |              |                         |                             | 0.069   |
| Aspirin and clopidogrel        | 97 (60.6)    | 58 (63.0)               | 39 (57.4)                   |         |
| Aspirin and ticagrelor         | 46 (28.8)    | 21 (22.8)               | 25 (36.8)                   |         |
| Aspirin and prasugrel          | 17 (10.6)    | 13 (14.1)               | 4 (5.9)                     |         |

Values are n (%) or mean ± standard deviation
ACS acute coronary syndrome, CABG coronary artery bypass grafting, CAD coronary artery disease, PCI percutaneous coronary intervention
*Includes unstable angina, non-ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction
### Table 2  Angiographic and procedural characteristics of patients in the protamine and non-protamine groups

|                        | All (n = 160) | Protamine group (n = 92) | Non-protamine group (n = 68) | p value |
|------------------------|--------------|-------------------------|-------------------------------|---------|
| Multivessel disease    | 119 (74.4)   | 67 (72.8)               | 52 (76.5)                     | 0.602   |
| Lesion type B2/C       | 131 (81.9)   | 77 (83.7)               | 54 (79.4)                     | 0.487   |
| Number of stents (per patient) | 2.4 ± 1.2 | 2.4 ± 1.3               | 2.4 ± 1.1                     | 0.963   |
| Treated lesion         |              |                         |                               |         |
| Unprotected left main disease | 36 (22.5) | 16 (17.4)               | 20 (29.4)                     | 0.072   |
| ≥ 3 lesions            | 26 (16.3)    | 15 (16.3)               | 11 (16.2)                     | 0.983   |
| Lesion length ≥ 60 mm  | 90 (56.3)    | 52 (56.5)               | 38 (55.9)                     | 0.936   |
| Bifurcation treated with two-stent technique | 33 (20.6) | 19 (16.9)               | 14 (20.6)                     | 0.873   |
| Chronic total occlusion| 78 (48.8)    | 57 (62.0)               | 21 (30.9)                     | <0.001  |
| Stent                  |              |                         |                               |         |
| Total length, mm       | 68.7 ± 39.2  | 68.9 ± 41.5             | 68.4 ± 36.1                   | 0.930   |
| Minimal diameter, mm   | 2.89 ± 0.42  | 2.89 ± 0.42             | 2.89 ± 0.41                   | 0.975   |
| Drug eluting stent      |              |                         |                               |         |
| Everolimus             | 98 (61.3)    | 58 (63.0)               | 40 (58.8)                     | 0.588   |
| Zotarlimus             | 49 (30.6)    | 29 (31.5)               | 20 (29.4)                     | 0.775   |
| Sirolimus              | 15 (9.4)     | 12 (13.0)               | 3 (4.4)                       | 0.098   |
| Biolimus               | 7 (4.4)      | 5 (5.4)                 | 2 (2.9)                       | 0.700   |
| Use of IVUS            | 160 (100)    | 92 (100)                | 68 (100)                      | –       |
| Sheath diameter        |              |                         |                               |         |
| 7 Fr                   | 144 (90.0)   | 80 (87.0)               | 64 (94.1)                     | 0.219   |
| 8 Fr                   | 26 (16.3)    | 18 (19.6)               | 8 (11.8)                      | 0.186   |
| Heparin dose, unit     | 8762.5 ± 1835.1 | 8788.0 ± 1851.3     | 8727.9 ± 1955.5               | 0.883   |
| ACT at the end of PCI, seconds | 316.8 ± 73.7 | 320.2 ± 76.0          | 293.9 ± 53.0                  | 0.252   |
| Protamine dose, mg     | –            | 45.9 ± 8.0              | –                             | –       |
| Procedural time, minutes | 1044 ± 56.1 | 1082 ± 55.5          | 99.2 ± 57.0                   | 0.317   |

Values are n (%) or mean ± standard deviation

ACT activated clotting time, IVUS intravascular ultrasound, PCI percutaneous coronary intervention

### Table 3  Clinical outcomes in the protamine and non-protamine groups

|                        | All (n = 160) | Protamine group (n = 92) | Non-protamine group (n = 68) | p value |
|------------------------|--------------|-------------------------|-------------------------------|---------|
| Primary outcome        | 16 (10.0)    | 4 (4.3)                 | 12 (17.6)                     | 0.006   |
| In-hospital death      | 2 (1.3)      | 0 (0.0)                 | 2 (2.9)                       | 0.179   |
| Myocardial infarction  | 0 (0.0)      | 0 (0.0)                 | 0 (0.0)                       | –       |
| Stent thrombosis       | 0 (0.0)      | 0 (0.0)                 | 0 (0.0)                       | –       |
| Stroke/systemic embolism | 1 (0.6)    | 0 (0.0)                 | 1 (1.5)                       | 0.425   |
| Bleeding requiring blood transfusion | 1 (0.6) | 1 (1.1)               | 0 (0.0)                       | 0.575   |
| Vascular access complications |              |                         |                               |         |
| Hematoma               | 12 (7.5)     | 3 (3.3)                 | 9 (13.2)                      | 0.020   |
| Pseudoaneurysm         | 0 (0.0)      | 0 (0.0)                 | 0 (0.0)                       | –       |
| Arteriovenous fistula  | 0 (0.0)      | 0 (0.0)                 | 0 (0.0)                       | –       |
| Surgical repair        | 0 (0.0)      | 0 (0.0)                 | 0 (0.0)                       | –       |
| In-hospital length of stay, (days) | 6.3 ± 6.3 | 4.8 ± 3.7              | 8.4 ± 8.3                     | 0.001   |

Values are n (%) or mean ± standard deviation
hematoma and without increasing any stent thrombosis and MI; and (3) patients with protamine administration had significantly shorter hospital stays than patients without protamine.

Although the incidence of bleeding complications after PCI has been decreasing, it remains the main challenge in complex PCI, which requires a femoral approach, larger sheath size, and more prolonged ACT. Stent thrombosis is a rare but serious complication of complex PCI due to procedure-related factors, such as bifurcation, long calcified lesions, and CTO [10]. Protamine has been used clinically for prompt reversal of the anticoagulant effect of heparin. Although protamine has been widely used in cardiovascular surgery [11] for a long time, it is underused for PCI because of the possible increase in the chances of hyperacute stent thrombosis, heparin rebound, and the potential for allergic or anaphylactic reactions [12]. Nevertheless, some
studies have investigated the safety of protamine use following PCI. De Luca et al. [5] performed a meta-analysis of randomized and non-randomized trials from 1990 to 2009 to evaluate the safety and benefits of protamine administration after coronary angiography, including bare-metal stents and first-generation DES. In this meta-analysis of 6762 patients, the rates of short-term mortality and MI were similar in both groups, with a significant reduction in major bleeding complications in patients receiving protamine. Yamamoto et al. [6] showed the safety of protamine following elective transfemoral PCI with the second-generation DES. They showed that the use of protamine after manual compression following elective transfemoral PCI was associated with fewer bleeding complications and protamine-treated patients did not sustain higher rates of stent thrombosis than non-protamine-treated patients, despite using DES. However, Yamamoto et al. [6] excluded patients with ACS who had a higher risk of bleeding and thrombosis than those with stable angina and did not describe the complexity of the lesion. In our study, we included patients who underwent only complex PCI, and more than 90% of the patients had ACS. Our study suggests that the administration of protamine is safe and does not increase the risk of stent thrombosis or MI.

Despite the inclusion of patients who underwent complex PCI with high anatomical risk, the reasons for the absence of stent thrombosis events in the protamine group should be considered. First, at the time of PCI, we only included patients who were already treated with DAPT, including new-generation P2Y12 inhibitors such as ticagrelor or prasugrel. DAPT has been established as a standard-of-care treatment for preventing stent-and non-stent-related ischemic events after PCI with DES [13–15]. Stent thrombosis appears to be significantly affected by the potency and rapidity of antiplatelet therapy, and the lack or delayed effect of antiplatelet agents has consistently been associated with a higher risk of stent thrombosis [16]. Compared with clopidogrel, ticagrelor and prasugrel, which have greater potency and faster action in inhibiting adenosine diphosphate–induced platelet aggregation; thus, they can reduce stent thrombosis regardless of stent type, the timing of stenting procedure, and ACS [17, 18]. Second, all patients in our study used second-generation DES, which has a lower rate of stent thrombosis than first-generation DES. First-generation DES platforms, which have relatively thick struts, durable polymer coating that can cause peri-strut inflammation, and paclitaxel that may cause delayed endothelialization, were associated with late and very late stent thrombosis [19, 20]. However, second-generation DES platforms have lower thrombogenicity due to more flexible and thinner struts, more biocompatible or biodegradable polymers, and limus drugs decrease neointimal response and increase re-endothelialization [21, 22]. Third, IVUS-guided PCI was performed in all patients in our study. PCI for complex lesions such as small-vessel disease, bifurcation, and long or highly calcified lesions is associated with a higher risk of malapposition, incomplete lesion coverage, under-expansion, and the likelihood of a slower or non-uniform pattern of endothelialization compared with simple PCI. In our study, optimal PCI with proper stent sizing and stent deployment using pre-intervention and post-intervention IVUS contributed to the reduction of stent thrombosis by aiming at no residual narrowing, absence of dissections, complete stent expansion, and good stent apposition [10, 23, 24].

This study had several limitations that should be addressed. This was a retrospective, non-randomized, single-center study. However, to the best of our knowledge, this is the first study to evaluate patients receiving heparin reversal with protamine for complex PCI. In addition, the relatively small study population may have affected the outcome. The cumulative incidence of stent thrombosis with DES at one year was very low at less than 1% [24]; therefore, the incidence of stent thrombosis may have been underestimated due to the small number of patients in this study. Anaphylactic reactions to protamine may also have been underestimated due to the small study population because they were very rare (<1%) and less likely to occur without protamine-containing insulin [25].

Conclusions
Among patients undergoing complex PCI via transfemoral access, immediate protamine use with manual compression after PCI resulted in significantly lower rates of the primary endpoint, driven mainly by significantly lower rates of vascular access complications, especially hematomas. In addition, protamine administration after complex PCI significantly shortened the hospital stay. Further prospective studies are needed to validate the safety and efficacy of protamine following complex PCI.

Abbreviations
PCI: Percutaneous coronary intervention; CTO: Chronic total occlusion; MI: Myocardial infarction; DAPT: Dual antiplatelet therapy; ACT: Activated clotting time; IVUS: Intravascular ultrasound; ACS: Acute coronary syndrome; DES: Drug-eluting stents.

Acknowledgements
Not applicable.

Author contributions
JC and KC made substantial contributions to the design of the present study. JC, SJ, SL, MC, and SL participated in data collection. JC, KC, KH, JK, YP and JK performed the statistical analysis. The draft of the manuscript was written by JC. All authors read and approved the final manuscript.
Funding
This work was supported for two years by a Pusan National University Research Grant. The funding played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets generated and/or analyzed during the current study are not publicly available due to privacy or ethical restrictions but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted in accordance with Declaration of Helsinki. This study was approved by the Institutional Review Board of the Pusan National University Yangsan Hospital (Approval No. 05-2020-105). The requirement for informed consent was waived owing to the retrospective nature of the study by Institutional Review Board of the Pusan National University Yangsan Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 22 February 2022  Accepted: 25 April 2022
Published online: 10 May 2022

References

1. Werner N, Nickenig G, Sinning JM. Complex PCI procedures: challenges for the interventional cardiologist. Clin Res Cardiol. 2018;107(Suppl 2):64–73.
2. Patel VG, Brayton KM, Tamayo A, Mogabgab O, Michael TT, Lo N, et al. Angiographic success and procedural complications in patients undergoing percutaneous coronary chronic total occlusion interventions: a weighted meta-analysis of 18,061 patients from 65 studies. JACC Cardiovasc Interv. 2017;10(2):128–36.
3. Noon VJ, Eldrup-Jorgensen J. A systematic review of vascular closure devices for femoral artery puncture sites. J Vasc Surg. 2018;68(3):887–99.
4. Sheth RA, Walker TG, Saad WE, Dariushnia SR, Gargiulii M, et al. Quality improvement guidelines for vascular access and closure device use. J Vasc Interv Radiol. 2014;25(1):73–84.
5. De Luca G, Parodi G, Antoniocci D. Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty: A meta-analysis. J Thromb Thrombolysis. 2010;30(4):452–8.
6. Yamamoto S, Sakakura K, Taniguchi Y, Yamamoto K, Wada H, Momomura SI, et al. Safety of reversing anticoagulation by protamine following elective transfemoral percutaneous coronary intervention in the drug-eluting stent era. Int Heart J. 2018;59(3):482–8.
7. Zago G, Trettin F, Prado GPA, Jr, Spadaro AG, Da Silva EER, et al. Early removal of the arterial sheath after percutaneous coronary intervention using the femoral approach: safety and efficacy study. Rev Bras Cardiol Invasiva Engl Ed. 2014;22(2):149–54.
8. Wakefield TW, Hantler CB, Wrobleski SK, Crider BA, Stanley JC. Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery. 1996;119(2):123–8.
9. Urdaneta F, Lobato EB, Kirby RR, Horow JC. Noncardiogenic pulmonary edema associated with protamine administration during coronary artery bypass graft surgery. J Clin Anesth. 1999;11(8):675–81.
10. Torrado J, Buckley L, Duran A, Trujillo P, Toldo S, Valle Ragh J, et al. Restenosis, stent thrombosis, and bleeding complications: aggravation between scylla and charybdis. J Am Coll Cardiol. 2018;71(15):1676–95.
11. Berger RL, Ramanavaswamy K, Ryan TJ. Reduced protamine dosage for heparin neutralization in open-heart operations. Circulation. 1968;37(4 Suppl):I1154–7.
12. Boer C, Meesters MI, Veeheohko D, Vonk ABA. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review. Br J Anaesth. 1998;80(2):914–27.
13. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasius R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334(17):1084–9.
14. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339(23):1665–71.
15. Giustino G, Barber U, Sartori S, Mehan R, Mastoris J, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015;66(13):1298–310.
16. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56(2):191–33.
17. Viviotti SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, et al. Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–63.
18. Steg P, Harrington R, Emanuelsson H, Katus H, Mahaffey K, Meier B, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013;128(10):1055–65.
19. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurrola PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesion). JACC Cardiovasc Interv. 2011;4(5):543–50.
20. Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211–23.
21. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurrola PA, Fitzgerald PJ, et al. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesion). JACC Cardiovasc Interv. 2011;4(5):1400–9.
22. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genrepeau P, Branzi A, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol. 2013;62(2):1915–21.
23. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91(6):1676–88.
24. Sanno G, Lagerqvist B, Frobert O, Nilsson J, Olveczova G, Omerovic E, et al. Lower risk of stent thrombosis and restenosis with unrestricted use of “new-generation” drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2012;33(5):606–13.
25. Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol. 2008;103(2):192–6.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.